Search results
Results from the WOW.Com Content Network
Curex is an American telehealth company specializing in immunology, specifically the diagnosis and treatment of allergies, including the prescription and delivery of allergy immunotherapy. [1] The company was founded by Gene Kakaulin and Charles Jacoby in 2020 [ 2 ] and is headquartered in New York City. [ 3 ]
Sublingual immunotherapy involves putting drops or a tablet of allergen extracts under the tongue, which are then absorbed through the lining of the mouth. Sublingual immunotherapy has been demonstrated to be effective against rhinoconjunctivitis and asthma symptoms. [16] This effectiveness, however, varies depending on the type of allergen. [16]
The sublingual route may also be used for vaccines against various infectious diseases. Thus, preclinical studies have found that sublingual vaccines can be highly immunogenic and may protect against influenza virus [4] [5] and Helicobacter pylori, [6] but sublingual administration may also be used for vaccines against other infectious diseases.
In 1992, ALK and Abello merged. In the 1990s, ALK was the first company to launch sublingual immunotherapy drops (allergy immunotherapy administered as droplets under the tongue). In recent years, ALK's research and development strategy has been focused on introducing a range of sublingual immunotherapy tablets (SLIT-tablets).
This page was last edited on 23 May 2020, at 19:04 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply ...
Buccal administration is a topical route of administration by which drugs held or applied in the buccal (/ ˈ b ʌ k əl /) area (in the cheek) diffuse through the oral mucosa (tissues which line the mouth) and enter directly into the bloodstream.
Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system. Immunotherapy is designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies .
Uromune, also known by its developmental code name MV-140, is a polyvalent bacterial vaccine which is used and is being developed for prevention of recurrent urinary tract infections (UTIs).